Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and ...

Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment ...

The government-funded insurance plan will now pay for the drug for patients with obstructive sleep apnea, a condition that ...

Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, ...

Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...

The number of layoffs in the U.S. pharmaceutical industry exceeded 14,000 last year, a 9% increase from 2023 ...

Dignity Health January marks Healthy Weight Awareness Month, and with the new year, many are setting health and weight loss ...

There is a photo that exemplifies the paradox of Robert F. Kennedy Jr.’s nomination as secretary of the Health and Human ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 494.50% and ...

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

Eli Lilly and Company’s LLY shares declined 13.5% in the past three months. Though demand for its popular tirzepatide drugs, Mounjaro and Zepbound, remains massive, their sales were hurt due to ...